Lanean...
Novel allosteric PARP1 inhibitors for the treatment of BRCA-deficient leukemia
The successful use of PARP1 inhibitors like olaparib (Loparza(®)) in the treatment of BRCA1/2- deficient breast cancer has provided clinical proof of concept for applying personalized medicine based on synthetic lethality to the treatment of cancer. Unfortunately, all marketed PARP1 inhibitors act b...
Gorde:
| Argitaratua izan da: | Med Chem Res |
|---|---|
| Egile Nagusiak: | , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7560981/ https://ncbi.nlm.nih.gov/pubmed/33071527 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00044-020-02537-0 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|